Semaglutide dose linked to lower mortality and cardiovascular risk in patients with baseline CVD
Why Ozempic's Heart Benefits May Have Nothing to Do With Weight Loss
An observational study of 47,199 patients with baseline cardiovascular disease in a U.S.
A massive real-world study of over 47,000 heart patients suggests that semaglutide may protect the heart through direct biological effects —…
Network meta-analysis of novel antidiabetic drugs in T2DM with CKD shows sotagliflozin, empagliflozin, and semaglutide rank highest for cardiovascular and renal outcomes
A Clear Winner Emerges for Diabetes Patients with Kidney Disease
This network meta-analysis evaluated novel antidiabetic drugs, including SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors, i…
For millions managing both diabetes and kidney disease, new research clarifies which medications offer the best protection for their heart a…
FDA Approves Dapagliflozin Tablets (dapagliflozin) for Type 2 Diabetes and Heart Failure Risk Reduction
FDA approves a new pill for type 2 diabetes that also helps protect the heart
The FDA has approved dapagliflozin tablets for two indications in adults with type 2 diabetes mellitus: to improve glycemic control and to r…
A new FDA-approved pill for type 2 diabetes now helps lower blood sugar while also reducing the risk of hospitalization for heart failure.
Meta-analysis finds SGLT2 inhibitors reduce mortality and hospitalization in older heart failure patients
Older Adults With Heart Failure May Gain Years From This Pill
A systematic review and meta-analysis of 20,844 patients aged 65+ with heart failure found SGLT2 inhibitors were associated with reduced all…
A pooled look at 10 studies in over 20,000 older adults shows SGLT2 inhibitors cut the risk of dying from any cause by about a fifth — and t…
FDA Approves Dapagliflozin Tablets (dapagliflozin) to Reduce Heart Failure Hospitalization Risk and Improve Glycemic Control in Adults with Type 2 Diabetes
FDA approves a diabetes drug that also helps protect the heart in certain adults
The FDA has approved dapagliflozin tablets to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus a…
A new diabetes drug is approved to lower blood sugar and cut the risk of heart failure hospitalization in adults with type 2 diabetes and he…
Self-management and glycemic control linked to lower MCI risk in rural elderly with type 2 diabetes
Better diabetes self-care linked to lower cognitive decline risk in rural elderly study
A cohort study of 232 rural Chinese elderly with type 2 diabetes found improved self-management behaviors, fewer depressive symptoms, and be…
Better diabetes self-care and mood control in older adults with type 2 diabetes were linked to a lower risk of memory problems in a rural Ch…
Structured exercise program improves glycemic control and fitness in Bangladeshi adults with type 2 diabetes
Can six weeks of guided exercise help manage diabetes better than medication alone?
A 6-week RCT in 90 Bangladeshi adults with type 2 diabetes found that adding a physiotherapist-led exercise program to medication improved c…
Six weeks of guided exercise alongside medication improved blood sugar, walking distance, and quality of life for adults with type 2 diabete…
SGLT2 inhibitors reduce weight and fat mass in older adults with T2DM, with smaller muscle mass decline
SGLT2 diabetes drugs reduce weight and fat in older adults, with small muscle loss
A meta-analysis of 8 RCTs in 541 older adults with Type 2 diabetes found SGLT2 inhibitors significantly reduced body weight (SMD=-0.85) and …
SGLT2 diabetes drugs help older adults lose weight and fat, but they also cause a small, measurable drop in muscle mass that doctors should …
SGLT2 inhibitors associated with lower mortality in ATTR-CM patients receiving disease-modifying therapy
Could a common diabetes drug help people with a serious heart condition live longer?
A meta-analysis of 7 observational studies including 7,283 patients with ATTR cardiomyopathy found SGLT2 inhibitor use was associated with l…
A common diabetes drug linked to lower death risk and fewer heart attacks for people with a serious heart condition called transthyretin amy…